ADOCIA Aktie [WKN DE: A1JTC2 / ISIN: FR0011184241]

Kurse + Charts + Realtime		News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (groß)	News + Adhoc	Bilanz/GuV	Termine	Zertifikate	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil	Optionsscheine	Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV	Knock-Outs
Historisch	Analysen

Kurse + Charts + Realtime
Kurs + Chart
Times + Sales
Börsenplätze
Historisch

News + Analysen
News + Adhoc
Analysen
Kursziele

Fundamental
Bilanz/GuV
Schätzungen
Dividende/GV
Analysen

Unternehmen
Termine
Profil

zugeh. Wertpapiere
Zertifikate
Optionsscheine
Knock-Outs

Nachrichten zu ADOCIA

12.02.18		Number of Shares and Voting Rights of ADOCIA as of January 31, 2018 (Businesswire)
12.02.18		Adocia: Additional Resources Allocated to the Liquidity Agreement (Businesswire)
09.02.18		Adocia to Present at the 2018 BIO CEO & Investor Conference in New York (Businesswire)
06.02.18		Adocia Files Additional Arbitration Claims Against Eli Lilly & Company (Businesswire)
25.01.18		Adocia Announces Positive Topline Data From a Dose-Proportionality Study of BioChaperone® Combo in People with Type 2 Diabetes (Businesswire)
10.01.18		Number of Shares and Voting Rights of ADOCIA as of December 31, 2017 (Businesswire)
09.01.18		Half Year Report on Adocia’s Liquidity Agreement with Kepler Capital Markets (Businesswire)
08.01.18		Adocia Announces Its Financial Calendar for 2018 (Businesswire)
04.01.18		Adocia Announces Expanded BioChaperone® Product Portfolio beyond Diabetes (Businesswire)
07.12.17		Number of Shares and Voting Rights of ADOCIA as of November 30, 2017 (Businesswire)
06.12.17		Adocia Announces Positive Topline Study Results Comparing Ultra-Rapid Insulin BioChaperone® Lispro with Novolog® and Fiasp® in People with Type 1 Diabetes (Businesswire)
20.11.17		Adocia Reports Topline Results of BioChaperone® Glucagon Phase 1 Study (Businesswire)
08.11.17		Number of Shares and Voting Rights of ADOCIA as of October 31, 2017 (Businesswire)
12.10.17		Number of Shares and Voting Rights of ADOCIA as of September 30, 2017 (Businesswire)
11.10.17		Adocia Announces Financial Results for the Third Quarter 2017 (Businesswire)
18.09.17		Number of Shares and Voting Rights of ADOCIA as of August 31, 2017 (Businesswire)
05.09.17		Adocia Announces Two Data Presentations at the 53rd Annual Meeting of the European Association for the Study of Diabetes (Businesswire)
26.07.17		Adocia Announces Appointment of Dr. Stanislav Glezer as Chief Medical Officer (Businesswire)
19.07.17		Adocia Presents First Half 2017 Financial Results (Businesswire)
30.05.17		Adocia Announces Six Data Presentations at the American Diabetes Association® 77th Scientific Sessions (Businesswire)
04.01.17		Adocia Announces Its Financial Calendar for 2017 (Businesswire)
10.11.16		Adocia to Participate in Upcoming Investor Conferences (Businesswire)
07.11.16		Adocia Receives the 1st Prize for ‘Profitable Growth’ and the 3rd ‘Technology Fast 50’ Prize as Part of The 2016 Deloitte In Extenso Technology Fast 50 Grand Rhône Alpes (Businesswire)
27.10.16		Adocia Announces Positive Topline Results from a Phase 1b Clinical Trial Measuring the Post-Meal Effect of Rapid-Acting Human Insulin, HinsBet® U100 (Businesswire)
12.10.16		Adocia Announces Third Quarter 2016 Financial Results (Businesswire)
22.09.16		Adocia Received the EY Global Company Award for the Auvergne Rhône-Alpes Region (Businesswire)
20.09.16		Adocia Launches a New Clinical Study of BioChaperone® Combo, Its Combination of Long-Acting Insulin Glargine and Fast-Acting Insulin Lispro, in People with Type 2 Diabetes (Businesswire)
19.09.16		Adocia to Hold Conference Call for Investors to Provide Business Update and Growth Perspectives (Businesswire)
08.09.16		Adocia to Present Clinical Data Validating BioChaperone® Technology at the 2016 EASD Annual Meeting (Businesswire)
07.09.16		Adocia Announces new BioChaperone Program Combining a Basal Insulin and GLP-1s (Businesswire)
21.07.16		Adocia Today Announces the Release of Its Interim Financial Report as of June 30, 2016 (Businesswire)
20.07.16		Adocia Presents First Half 2016 Financial Results (Businesswire)
05.07.16		Half Year Report on Adocia’s Liquidity Agreement with Kepler Capital Markets (Businesswire)
08.06.16		Adocia Reinforces Its Focus on Diabetes with the Launch of a New Project: BioChaperone Glucagon (Businesswire)
06.06.16		Adocia to Present Data Validating the Potential of BioChaperone® Technology at the American Diabetes Association® 76Th Scientific Sessions (Businesswire)
02.06.16		Adocia to Present at the Jefferies 2016 Global Healthcare Conference (Businesswire)
31.05.16		Adocia and Lilly Announce Positive Topline Results from a Phase 1 Study Evaluating Ultra-Rapid Insulin BioChaperone Lispro U100 in Healthy Japanese Subjects (Businesswire)
13.05.16		Adocia to Hold Its Annual Shareholders’ Meeting on June 21, 2016 in Paris (Businesswire)
03.05.16		Adocia strengthens its BioChaperone Combo patent portfolio (Businesswire)
27.04.16		Adocia and Lilly Announce Positive Topline Results from a Phase 1b Study of Repeated Administration of Ultra-Rapid BioChaperone Lispro U100 in People with Type 2 Diabetes (Businesswire)
14.04.16		Adocia Announces First Quarter 2016 Results (Businesswire)
11.04.16		Adocia Initiates a Phase 1/2 Clinical Trial on the Post-Meal Effect of Rapid-Acting Human Insulin, HinsBet® U100 (Businesswire)
25.03.16		ADOCIA Confirms Its Eligibility for the PEA - PME (Businesswire)
21.03.16		Adocia Welcomes Internationally Renowned Diabetes Experts to Inaugural Medical Advisory Board (Businesswire)
16.03.16		ADOCIA Announced Its Financial Results for 2015 (Businesswire)
14.03.16		Adocia and Lilly Announce Positive Topline Results from a Phase 1b Study of Repeated Administration of Ultra-Rapid BioChaperone Lispro in Patients with Type 1 Diabetes (Businesswire)
16.02.16		Adocia Announced Significant Revenue Growth With EUR 36.9 Million (EUR 0.7 Million in 2014) in Revenue and a Solid Cash Position Of EUR 72 Million as of December 31, 2015 (Businesswire)
04.02.16		Adocia to Present at the 2016 Leerink Global Healthcare Conference (Businesswire)
29.01.16		Adocia and Lilly Initiate Phase 1b Study Evaluating Ultra-Rapid Insulin BioChaperone Lispro U100 in Healthy Japanese Subjects (Businesswire)
08.01.16		Half year report on Adocia’s liquidity agreement with Kepler Capital Markets (Businesswire)

1 | Weiter

Newssuche

Meistgelesene Nachrichten

Bitcoin als Chance: MicroStrategy-Chef fordert Microsoft zu mutigem Schritt auf

CompuGroup-Aktie mit zweistelligem Plus: CVC bestätigt Akquisition

Bayer-Aktie erholt sich weiter: Glyphosat-Fehlprozess in USA

Neue Kooperationsvereinbarung: Palantir-Aktie erreicht neues Rekordhoch - und sackt dann ab

Generative KI: Warum der NVIDIA-CEO auf Accenture setzt

voestalpine-Aktie gewinnt: Wiener Privatbank senkt Kursziel

finanzen.net Apps

ETF-Sparplan

Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.

JETZT MEHR ERFAHREN

Aktien ATX DAX EuroStoxx 50 Dow Jones NASDAQ 100 Nikkei 225 S&P 500

Kontakt - Impressum - Werbung

Sitemap - Datenschutz - Disclaimer - AGB - Privatsphäre-Einstellungen

Für die aufgeführten Inhalte kann keine Gewährleistung für die Vollständigkeit, Richtigkeit und Genauigkeit übernommen werden.
Kursinformationen von SIX Financial Information Deutschland GmbH. Verzögerung 15 Min. (Nasdaq, NYSE: 20 Min.).
© 1999-2024 finanzen.net GmbH

*Werbehinweise: Die Billigung des Basisprospekts durch die Bundesanstalt für Finanzdienstleistungsaufsicht ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.

⁵Hinweis zu Plus500: 82% der Kleinanlegerkonten verlieren Geld beim CFD-Handel mit diesem Anbieter. Sie sollten überlegen, ob Sie es sich leisten können, das hohe Risiko einzugehen, Ihr Geld zu verlieren. Plus500UK Ltd ist zugelassen und reguliert durch Financial Conduct Authority (FRN 509909). Plus500CY Ltd authorized & regulated by CySEC (#250/14).

Währungsrechner News Devisen Dollarkurs Aktienkurse Bitcoin Rohstoffe Fonds

Portfolioname: Watchlistname:
Portfolio:
Name:
Typ:
ISIN:
Börse:
Anzahl:
Aktueller Kurs:
Kurszeit:
Kaufpreis:
Kaufdatum:	11.12.2024 22:23
Kaufwert:	EUR
	Hinzufügen Speichern